14.2 Monotherapy Use of MOUNJARO in Adult Patients with Type 2 Diabetes Mellitus SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg, or placebo once weekly
doi.org/10.1038/nature03000 Dalmasso, G., et al
How Peptides and Secretagogues Work for Recovery Injectable peptides and growth hormone secretagogues (GHSs) accelerate recovery by activating repair pathways at the cellular and molecular level
FACS analysis confirmed that at passage 10, 54.7% of EpCAM+ HBs co-expressed the proliferative marker Ki67, and immunostaining showed sustained co-expression of AFP, HNF4, and Ki67
Another doctor who had weaned me off in years before was now the one wanting me back on